{"id":"norursodeoxycholic-acid","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Abdominal pain"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"FXR agonists like norUrsodeoxycholic acid work by activating the farnesoid X receptor, which plays a key role in regulating bile acid synthesis and transport. This can lead to reduced bile acid levels in the liver and improved liver function.","oneSentence":"NorUrsodeoxycholic acid is a bile acid that acts as an FXR agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:31.350Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary biliary cholangitis"}]},"trialDetails":[{"nctId":"NCT06886360","phase":"PHASE3","title":"Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)","status":"NOT_YET_RECRUITING","sponsor":"Dr. Falk Pharma GmbH","startDate":"2025-03","conditions":"Primary Sclerosing Cholangitis","enrollment":120},{"nctId":"NCT03872921","phase":"PHASE3","title":"norUrsodeoxycholic Acid vs Placebo in PSC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dr. Falk Pharma GmbH","startDate":"2018-02-08","conditions":"Primary Sclerosing Cholangitis","enrollment":303},{"nctId":"NCT05083390","phase":"PHASE2","title":"Norursodeoxycholic Acid vs. Placebo in NASH","status":"UNKNOWN","sponsor":"Dr. Falk Pharma GmbH","startDate":"2019-07-08","conditions":"Nonalcoholic Steatohepatitis","enrollment":363},{"nctId":"NCT01755507","phase":"PHASE2","title":"Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis","status":"COMPLETED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2012-12","conditions":"Primary Sclerosing Cholangitis","enrollment":159}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["norucholic acid","norUDCA","NCA","NUC"],"phase":"phase_3","status":"active","brandName":"norUrsodeoxycholic acid","genericName":"norUrsodeoxycholic acid","companyName":"Dr. Falk Pharma GmbH","companyId":"dr-falk-pharma-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NorUrsodeoxycholic acid is a bile acid that acts as an FXR agonist. Used for Primary biliary cholangitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}